Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4

Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here. The fund rose 13.10% (Institutional Shares) in the quarter, compared to a 11.92% gain for the Russell 3000 Health Care Index (benchmark) and a 2.40% gain for the Russell 3000 Index (the Index). The Fund returned 10.28% for the full year, compared to 14.56% and 17.15% gains for the indexes, respectively. Strong stock selection in biotechnology contributed to the Fund’s relative gains in the quarter.  The Fund seeks to invest in businesses with secular growth opportunities, a sustainable competitive edge, and strong management. The firm believes that healthcare is a strong sector in the U.S. economy, offering attractive investment opportunities with positive momentum heading into 2026.  Please review the Fund’s top five holdings to gain insights into their key selections for 2025.

In its fourth-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Argenx SE (NASDAQ:ARGX). Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company and a leading contributor to the fund’s quarterly performance. The one-month return of Argenx SE (NASDAQ:ARGX) was 4.04%, and its shares gained 26.86% of their value over the last 52 weeks. On February 5, 2026, Argenx SE (NASDAQ:ARGX) stock closed at $820.31 per share, with a market capitalization of $50.764 billion.

Baron Health Care Fund stated the following regarding Argenx SE (NASDAQ:ARGX) in its fourth quarter 2025 investor letter:

“Argenx SE (NASDAQ:ARGX) is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose as Vyvgart sales meaningfully exceeded investor expectations. Our conversations with management and neurologists continue to reinforce Vyvgart’s value as an important treatment option with strong long-term growth potential. The drug continues to launch well in generalized myasthenia gravis, and its launch in chronic inflammatory demyelinating polyneuropathy is off to a strong start. Over time, we expect Vyvgart to demonstrate efficacy across an expanding range of autoantibody-driven autoimmune conditions, and we are excited by argenx’s pipeline progress and upcoming Phase 3 readouts for Vyvgart in myositis and empasiprubart in multifocal motor neuropathy.”

Is argenx SE (ARGX) the Best Cancer Stock to Invest in for Long-Term Gain?

Argenx SE (NASDAQ:ARGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 50 hedge fund portfolios held Argenx SE (NASDAQ:ARGX) at the end of the third quarter, up from 53 in the previous quarter. While we acknowledge the risk and potential of Argenx SE (NASDAQ:ARGX) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Argenx SE (NASDAQ:ARGX) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Argenx SE (NASDAQ:ARGX) and shared the list of best NASDAQ growth stocks to buy for the next 10 years. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.